Skip to search formSkip to main contentSkip to account menu

NEUTROPHIL-ACTIVATING PEPTIDE 2

Known as: CATP-III (de 1-15), connective tissue activating peptide-III (des 1-15), neutrophil activating peptide-2 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
OBJECTIVE We measured the levels of neutrophil activating peptide-2 (NAP-2) and pentraxin-3 (PTX-3) in acute coronary syndromes… 
2007
2007
AIM The aim of this study was to evaluate the inflammatory reactions in patients with thoracic aortic aneurysms before, during… 
2003
2003
Background:  We previously reported that the expressions of two CXC chemokines, neutrophil activating peptide‐2 (NAP‐2) and… 
2002
2002
In the presence of thrombopoietin (TPO), megakaryocytes mature by polyploidization and cytoplasmic maturation, and the matured… 
Highly Cited
1998
Highly Cited
1998
Heparin-induced thrombocytopenia (HIT) is a potentially serious complication of heparin therapy. Antibodies to platelet factor 4… 
1998
1998
Heparin-induced thrombocytopenia (HIT) is a potentially serious complication of heparin therapy. Antibodies to platelet factor 4… 
Highly Cited
1995
Highly Cited
1995
We have previously shown that platelet factor 4 (PF4), a platelet-specific CXC chemokine, can directly and specifically inhibit… 
Highly Cited
1993
Highly Cited
1993
We have tested the histamine releasing properties and priming abilities of a wide range of recombinant or purified cytokines and…